written on 16.01.2014

Biocon: anticancer biologics still largely unaffordable


Biocon, which is set to launch soon in India a biosimilar version of Roche's Herceptin (trastuzumab), indicated how the number of days' wages required to purchase a month's course of cancer antibody treatment varied from 371 in Southeast Asia, 1,285 in…